1. Successful Hepatorenal Transplantation in Hereditary Amyloidosis Caused by a Frame-Shift Mutation in Fibrinogen Aa -Chain Gene
- Author
-
Christiane Mousson, Bruno Heyd, Y. Tanter, Jean-Philippe Miguet, Gérard Rifle, Jean-Michel Rebibou, Eve Justrabo, Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de chirurgie viscérale et digestive - Unité de transplantation hépatique, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire de pathologie, Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Saas, Philippe
- Subjects
Adult ,Male ,MESH: Liver Transplantation ,Pathology ,medicine.medical_specialty ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Biopsy ,medicine.medical_treatment ,030232 urology & nephrology ,030204 cardiovascular system & hematology ,Liver transplantation ,Fibrinogen ,Renal amyloidosis ,MESH: Kidney Transplantation ,Frameshift mutation ,MESH: Biopsy ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Immunology and Allergy ,Pharmacology (medical) ,Frameshift Mutation ,Kidney transplantation ,Transplantation ,Kidney ,MESH: Humans ,business.industry ,Amyloidosis ,MESH: DNA ,MESH: Frameshift Mutation ,MESH: Adult ,DNA ,MESH: Follow-Up Studies ,MESH: Amyloidosis, Familial ,medicine.disease ,Kidney Transplantation ,MESH: Male ,Liver Transplantation ,3. Good health ,medicine.anatomical_structure ,MESH: Fibrinogen ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,Amyloidosis, Familial ,Follow-Up Studies ,medicine.drug - Abstract
International audience; Hereditary systemic amyloidosis comprises several autosomal dominant diseases caused by mutations in a number of plasma proteins, including the fibrinogen Aalpha-chain. Four mutations in the fibrinogen Aalpha-chain that are able to induce amyloidosis have been identified so far, the most common being the Glu526Val mutation. We have observed a family in which the father and his son reached end-stage renal failure because of renal amyloidosis induced by a frame-shift mutation in the fibrinogen Aalpha-chain gene producing a novel amyloid protein. Two kidney transplantations in the father and one in the son resulted in fast graft loss caused by recurrence of amyloid deposition. We then performed hepatorenal transplantation in the son. Three years later, liver and kidney functions are normal without recurrence of amyloid deposition. This case, together with three others with the Glu526Val mutation in the extensive literature, suggests that liver transplantation can cure hereditary fibrinogen amyloidosis, whatever the mutation may be.
- Published
- 2006
- Full Text
- View/download PDF